Similar articles

• The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.

  Eschbach JW, Haley NR, Adamson JW. Eschbach JW, et al. Contrib Nephrol. 1990;78:24-36; discussion 37. Contrib Nephrol. 1990. PMID: 2225841 Review. No abstract available.
• Analysis of initial resistance of erythropoiesis to treatment with recombinant human erythropoietin. Results of a multicenter trial in patients with end-stage renal disease.

  Kühn K, Nonnast-Daniel B, Grützmacher P, Grüner J, Pfåffl W, Baldamus CA, Scigalla P. Kühn K, et al. Contrib Nephrol. 1988;66:94-103. Contrib Nephrol. 1988. PMID: 3292152 Clinical Trial. No abstract available.
• Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease.

  Bommer J, Kugel M, Schoeppe W, Brunkhorst R, Samtleben W, Bramsiepe P, Scigalla P. Bommer J, et al. Contrib Nephrol. 1988;66:85-93. Contrib Nephrol. 1988. PMID: 3292151 Clinical Trial. No abstract available.
• [The effect of recombinant human erythropoietin on erythrocyte lines in patients with anemia and chronic renal insufficiency].

  Marisavljević D, Djukanović Lj, Lezajić V. Marisavljević D, et al. Srp Arh Celok Lek. 1992 Sep-Oct;120(9-10):281-5. Srp Arh Celok Lek. 1992. PMID: 1306020 Serbian.
• Modern aspects of the pathophysiology of renal anemia.

  Eschbach JW, Adamson JW. Eschbach JW, et al. Contrib Nephrol. 1988;66:63-70. doi: 10.1159/000416004. Contrib Nephrol. 1988. PMID: 3292149 Review. No abstract available.